Oxaliplatin Kelix Bio (Oxaliplatin)

Oxaliplatin Kelix Bio is a platinum‑based chemotherapeutic agent used in the treatment of cancers that respond to DNA‑cross‑linking therapy.

• Colorectal cancer: improves survival when combined with fluoropyrimidine‑based regimens.
• Gastric cancer: used in combination protocols for advanced disease.
• Pancreatic cancer: part of multi‑drug regimens for metastatic cases.

• Oxaliplatin forms covalent bonds with DNA, creating intra‑ and interstrand cross‑links that disrupt DNA replication and transcription. The resulting DNA damage triggers cell‑cycle arrest and apoptosis, particularly in rapidly dividing tumor cells. Its platinum core distinguishes it from older agents, providing activity against tumors resistant to other platinum compounds.

Oxaliplatin may cause a range of adverse reactions, from mild to severe, depending on individual tolerance and treatment context.

Common Side Effects

• Nausea and vomiting: mild to moderate gastrointestinal upset.
• Peripheral neuropathy: tingling or numbness, often dose‑related.
• Fatigue: general tiredness during treatment cycles.
• Diarrhea: loose stools that may require supportive care.
• Elevated liver enzymes: transient changes in hepatic function tests.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: anaphylaxis‑like symptoms requiring immediate medical attention.
• Hematologic toxicity: neutropenia or thrombocytopenia increasing infection or bleeding risk.
• Acute pulmonary toxicity: rare lung inflammation presenting with cough or dyspnea.
• Cardiac arrhythmias: uncommon but potentially life‑threatening rhythm disturbances.
• Renal impairment: worsening kidney function, especially with pre‑existing disease.

When using Oxaliplatin Kelix Bio, clinicians should assess patient suitability and monitor for known risks.

• Renal function: evaluate creatinine clearance before each cycle.
• Hepatic function: check liver enzymes and bilirubin regularly.
• Neuropathy monitoring: assess sensory changes and adjust dosing if needed.
• Hematologic surveillance: perform complete blood counts to detect neutropenia or thrombocytopenia.
• Allergic reactions: be prepared to manage infusion‑related hypersensitivity.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Oxaliplatin may interact with several concomitant medications, influencing efficacy or safety.

Major Interactions (Avoid)

• Nephrotoxic agents (e.g., cisplatin, aminoglycosides): increase risk of kidney damage.
• High‑dose vitamin C infusions: may reduce platinum‑drug activity.

Moderate Interactions (Monitor Closely)

• Anticoagulants (warfarin, DOACs): heightened bleeding risk due to thrombocytopenia.
• Antiemetics (ondansetron, dexamethasone): may require dose adjustments for optimal control.
• CYP450 inducers (rifampicin): potential alteration of drug clearance.
• Immunosuppressants (cyclophosphamide): additive bone‑marrow suppression.
• NSAIDs (ibuprofen, naproxen): may exacerbate renal toxicity.